Perrigo Company (PRGO) 166.11 $PRGO
Stocks Off Highs But Stay Positive; Nike Drags Dow
at Investor's Business Daily - Fri Dec 19, 12:27PM CST
Stocks stayed positive but were off session highs Friday afternoon. The Nasdaq was up 0.2%, while the S&P 500 added 0.1% and the Dow dipped 0.1%. Volume was tracking higher in the stock market today amid quadruple witching of options and futures. The...
PRGO: 166.11 (+1.96), CTAS: 79.86 (+0.22), GILD: 91.29 (+1.84), NKE: 96.29 (+0.32)
Perrigo (PRGO) Is Today's Momo Momentum Stock
at The Street - Fri Dec 19, 8:50AM CST
Trade-Ideas LLC identified Perrigo (PRGO) as a momo momentum candidate
PRGO: 166.11 (+1.96)
Perrigo Set to Possibly Pullback After Yesterday's Rally of 3.50%
Comtex SmarTrend(R) - Wed Dec 17, 4:33PM CST
Perrigo (NASDAQ

RGO) traded in a range yesterday that spanned from a low of $154.55 to a high of $159.44. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $156.92 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 166.11 (+1.96)
Dividend Contenders: 30 Increases Expected By The End Of February
David Fish - at Seeking Alpha - Sat Dec 13, 1:50PM CST

78.38 (+1.48), MDP: 53.04 (-0.89), ROP: 159.75 (+0.21), LARK: 20.90 (-0.53), PRGO: 166.11 (+1.96), JBHT: 84.91 (-0.02), NU: 55.02 (+1.27), TRI: 40.98 (+0.27), AOS: 56.19 (+0.17), PRE: 114.49 (-0.15), ROL: 33.38 (-0.18), PII: 150.40 (+0.38), CHD: 80.16 (-0.37), TGP: 42.06 (-0.60), GAS: 54.01 (+1.29), LLTC: 46.66 (+0.23), EBTC: 24.47 (-0.20), CMP: 87.48 (+0.37), NEE: 107.98 (+1.66), AVA: 35.84 (+0.66), RHI: 58.91 (+0.05), JKHY: 63.50 (-0.07), ADI: 56.71 (+0.05), CVS: 97.89 (+0.02), ANDE: 55.10 (+0.35), LLL: 128.34 (+0.07), LNT: 67.41 (+1.10)
Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Senior Notes
PR Newswire - Tue Dec 02, 12:31PM CST
Perrigo Company plc ("Perrigo"

(NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously announced registered public offering by Perrigo Finance plc, a public limited company incorporated under the laws of Ireland and a finance subsidiary of Perrigo (the "Issuer"

, of $1.6 billion Senior Notes consisting of $500 million aggregate principal amount of 3.50% Senior Notes due 2021 (the "2021 Notes"

, $700 million aggregate principal amount of 3.90% Senior Notes due 2024 (the "2024 Notes"

and $400 million aggregate principal amount of 4.90% Senior Notes due 2044 (the "2044 Notes" and, together with the 2021 Notes and the 2024 Notes, the "Notes"

. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Perrigo.
PRGO: 166.11 (+1.96)
Perrigo Announces FDA Approval And Launch Of The Generic Version Of Pennsaid® 1.5% w/w
PR Newswire - Tue Dec 02, 7:48AM CST
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for diclofenac sodium topical solution 1.5% w/w. Shipments to our pharmacy customers have commenced.
PRGO: 166.11 (+1.96)
Market Movers - Pharma Industry Stocks - Hospira, Perrigo, Auxilium Pharma, Depomed, and Endo Intl.
PR Newswire - Mon Dec 01, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Perrigo Company PLC (NYSE: PRGO), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), and Endo International PLC (NASDAQ: ENDP). Free research on these five companies can be accessed at:
http://investor-edge.com/register. The US markets on Friday, November 28, 2014, ended on a mixed note as the Dow Jones Industrial Average finished flat at 17,828.24 and the NASDAQ Composite closed at 4,791.63, up 0.09%. The S&P 500 finished the session 0.25% lower at 2,067.56. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.65, up 0.58%, with the index advancing 8.95% in the previous three months. Register for your complimentary reports on these five stocks at:
ENDP: 72.10 (+0.34), PRGO: 166.11 (+1.96), AUXL: 34.40 (+0.18), DEPO: 15.54 (+0.38), HSP: 62.60 (-0.07)
Perrigo Company concludes public offering at USD152.00 per share
M2 - Thu Nov 27, 4:14AM CST
Healthcare company Perrigo Company (NYSE

RGO) said on Wednesday that it has closed its public offering of 6,809,210 ordinary shares at a public offering price of USD152.00 per share.
PRGO: 166.11 (+1.96)
After Yesterday's Rally of 1.77% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Nov 26, 4:24PM CST
Perrigo (NASDAQ

RGO) traded in a range yesterday that spanned from a low of $156.72 to a high of $159.35. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $158.24 on volume of 738,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 166.11 (+1.96)
Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares
PR Newswire - Wed Nov 26, 10:51AM CST
Perrigo Company plc ("Perrigo"

(NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of Perrigo's previously announced registered public offering relating to the sale of 6,809,210 ordinary shares at a public offering price of $152.00 per share, including the full exercise of the option to purchase up to an additional 888,157 ordinary shares by J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters.
PRGO: 166.11 (+1.96)
Perrigo closes debt offering
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 2:56PM CST
PRGO: 166.11 (+1.96)
Perrigo Company's underwriters exercise option to purchase another 888,157 ordinary shares
M2 - Tue Nov 25, 8:44AM CST
Healthcare company Perrigo Company (NYSE

RGO) said on Monday that its underwriters have exercised their option, in full, to purchase an additional 888,157 ordinary shares at USD152.00 per share, less the underwriting discount.
PRGO: 166.11 (+1.96)
Perrigo Company intends to issue senior notes in public offering
M2 - Tue Nov 25, 8:39AM CST
Healthcare company Perrigo Company (NYSE

RGO) reported on Monday the start of its public offering of three series of senior notes through its finance subsidiary, Perrigo Finance.
PRGO: 166.11 (+1.96)
Perrigo unveils generic Protopic Ointment 0.1% And 0.03% for treating eczema
M2 - Tue Nov 25, 8:34AM CST
Healthcare company Perrigo Company (NYSE

RGO) said on Monday that it has launched the authorised generic version of Protopic Ointment 0.1% and 0.03% in the market.
PRGO: 166.11 (+1.96)
Perrigo Company plc Announces The Pricing Of Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance plc
PR Newswire - Mon Nov 24, 3:42PM CST
Perrigo Company plc ("Perrigo"

(NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the registered public offering by Perrigo Finance plc, a public limited company incorporated under the laws of Ireland and a finance subsidiary of Perrigo (the "Issuer"

, of $1.6 billion Senior Notes consisting of $500 million aggregate principal amount of 3.50% Senior Notes due 2021 (the "2021 Notes"

, $700 million aggregate principal amount of 3.90% Senior Notes due 2024 (the "2024 Notes"

and $400 million aggregate principal amount of 4.90% Senior Notes due 2044 (the "2044 Notes" and, together with the 2021 Notes and the 2024 Notes, the "Notes"

. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Perrigo. The 2021 Notes were sold at a public offering price of 99.937% of the aggregate principal amount thereof, the 2024 Notes were sold at a public offering price of 99.579% of the aggregate principal amount thereof and the 2044 Notes were sold at a public offering price of 99.701% of the aggregate principal amount thereof.
PRGO: 166.11 (+1.96)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Perrigo Is Up 1.3% (PRGO)
Comtex SmarTrend(R) - Mon Nov 24, 9:17AM CST
18 days ago, on November 6th, 2014, Perrigo (NASDAQ

RGO) reported its earnings. Analysts, on average, expected earnings of $1.45 per share on sales of $997.9 million. The company actually reported EPS of $1.40 on sales of $951.5 million, missing EPS estimates by $0.05 and missing revenue estimates by $46.4 million. Since the company's report, shares of Perrigo have risen from $152.49 to $154.50, representing a gain of 1.3% in the past 18 days.
PRGO: 166.11 (+1.96)
Perrigo Company plc Announces Underwriters' Full Exercise Of Option To Purchase Ordinary Shares In Connection With The Equity Offering
PR Newswire - Mon Nov 24, 7:48AM CST
Perrigo Company plc ("Perrigo"

(NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that the underwriters for Perrigo's previously announced public equity offering of 5,921,053 ordinary shares exercised their option, in full, to purchase an additional 888,157 ordinary shares of Perrigo at $152.00 per share, less the underwriting discount (collectively, the "Equity Offering"

.
PRGO: 166.11 (+1.96)
Perrigo Company plc Announces Proposed Public Offering Of Senior Notes Of Its Finance Subsidiary, Perrigo Finance plc
PR Newswire - Mon Nov 24, 7:47AM CST
Perrigo Company plc ("Perrigo"

(NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that Perrigo Finance plc, a finance subsidiary of Perrigo incorporated under the laws of Ireland (the "Issuer"

, commenced a registered public offering of three series of Senior Notes (collectively, the "Notes"

. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by the Company. The exact terms and timing of the offering will depend upon market conditions and other factors.
PRGO: 166.11 (+1.96)
Comparing The 3 Largest Drug Related Products Companies
Joseph Cafariello - at Seeking Alpha - Mon Nov 24, 6:58AM CST
PRGO: 166.11 (+1.96), AUXL: 34.40 (+0.18), USNA: 103.51 (+0.91)
Perrigo Confirms First to File Patent Challenge for Generic Version of Aveed® (Testosterone Undecanoate) Injection
PR Newswire - Mon Nov 24, 6:54AM CST
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone undecanoate injection and that it has notified the owner of the Reference Listed Drug of its filing.
PRGO: 166.11 (+1.96)